Comparison Study of Dendritic Cell Vaccine with and without Cyclophosphamide to Treat Stage IV Melanoma Patients

Article

This trial is evaluating whether the combination of chemotherapy (cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.

Study Type: Interventional

Age/Sex Requirement: 21-75 years (None)

Sponsor: Baylor Research Institute

ClinicalTrials.gov Identifier: NCT00722098

Purpose: To determine whether the combination of chemotherapy (cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.

Click here to learn more about the clinical trial.

Related Videos
3 KOLs are featured in this program.
3 KOLs are featured in this program.
Atul Malhotra, MD | Credit: Kyle Dykes; UC San Diego Health
A panel of 4 experts on HIV
A panel of 4 experts on HIV
Edward V Loftus, Jr, MD | Credit: Mayo Clinic
A panel of 4 experts on asthma
A panel of 4 experts on asthma
Katie Ross-Driscoll, PhD, MPH | Credit: Regenstrief Institute
© 2024 MJH Life Sciences

All rights reserved.